ERBB2 and non-small cell lung carcinoma: Amplification of HER2 is observed in only 1% of chemo-naïve patients with NSCLC, but this proportion increases to 12% in EGFR TKI-resistant tumors, suggesting that the overexpression of HER2 may contribute to resistance [111].